{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:04:42Z","timestamp":1784009082954,"version":"3.55.0"},"reference-count":50,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":193,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Hypertension"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the patient characteristics, effectiveness, safety, adherence, and persistence of ramipril\/indapamide (R\/I) free combination therapy in patients with essential hypertension inadequately controlled with monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational cohort study used anonymized UK primary care electronic health records from IQVIA\u2019s Medical Research Database (IMRD), incorporating \u201cThe Health Improvement Network\u201d (THIN), a Cegedim Database. Adults with essential hypertension who switched from ramipril or indapamide monotherapy to R\/I between database inception and January 1, 2021, were enrolled. Outcomes included changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP), proportions achieving BP\u2009&lt;\u2009140\/90\u2009mmHg or SBP \u2265 20\u2009mmHg\/DBP \u2265 10\u2009mmHg decrease, proportion of days covered (PDC), persistence, and adverse events (AEs) over 12\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1089 patients met inclusion criteria (mean age 63.5\u2009years; 55.6% female). Mean baseline BP on monotherapy was 156.0\/89.1\u2009mmHg. Over 12\u2009months, mean SBP decreased by 18.7\u2009mmHg and DBP by 8.9\u2009mmHg (both\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001); 54.3% of patients achieved BP\u2009&lt;\u2009140\/90\u2009mmHg, and 61.6% met the predefined BP decrease threshold. A dose\u2013response relationship was observed for BP outcomes. Mean PDC was 92.4% at 3\u2009months and 86.2% at 12\u2009months; persistence was 87.7% and 81.5%, respectively. The most frequent AE was cough (10.38%); gout occurred in 0.73%, exclusively in indapamide\u2010na\u00efve patients. The outcomes remained consistent across sensitivity and subgroup analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Switching from ramipril or indapamide monotherapy to their free combination was associated with clinically meaningful BP decreases, high adherence and persistence, and a favorable safety profile in routine practice. These findings are consistent with current therapeutic guidelines that endorse its use in essential hypertension management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1155\/ijhy\/1999424","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:32:14Z","timestamp":1784007134000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010World Effectiveness and Safety of Ramipril\/Indapamide Combination Therapy in Essential Hypertension: A Retrospective Study on UK Primary Care Records"],"prefix":"10.1155","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0054-900X","authenticated-orcid":false,"given":"Mariusz","family":"Mogielnicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"P\u0142aszczyca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6098-0365","authenticated-orcid":false,"given":"Andrew","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Piechaczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quirino","family":"Schefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5877-4900","authenticated-orcid":false,"given":"Volodymyr","family":"Stus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"e_1_2_11_1_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003480"},{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf659"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200306000-00001"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.3317\/jraas.2000.002"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002088"},{"key":"e_1_2_11_7_2","unstructured":"S.A. Servier Benelux N.V. SmPC Fludex 2 5 mg Comprim\u00e9s Enrobes 2021 https:\/\/app.fagg-afmps.be\/pharma-status\/api\/files\/62bc87691e5c015ab30d3595 Accessed July 23 2025."},{"key":"e_1_2_11_8_2","unstructured":"European Medicines Agency Questions and Answers on the Referral for Tritace Tablet and Hard Capsules Containing Ramipril 1.25 Mg 2.5 Mg 5 Mg and 10 Mg. Doc. Ref. EMEA\/CHMP\/233264\/2009 2009 https:\/\/www.ema.europa.eu\/en\/documents\/referral\/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_en.pdf Accessed July 23 2025."},{"key":"e_1_2_11_9_2","article-title":"MRI Product Index","author":"Heads of Medicines Agencies","journal-title":"Polpril Plus. PL\/H\/0928\/001"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3079"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.03072.x"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001947"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015527"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.2782"},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1295174"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4891"},{"key":"e_1_2_11_18_2","volume-title":"Hypertension in Adults: Diagnosis and Management","author":"National Institute of Health and Care Excellence","year":"2019"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4884"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010316.pub3"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90944-z"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-022-01706-4"},{"key":"e_1_2_11_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960151210"},{"key":"e_1_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006986"},{"key":"e_1_2_11_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000177112"},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000198987.34588.11"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.15829\/1560-4071-2021-4651"},{"key":"e_1_2_11_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.123.21725"},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2024.2363401"},{"key":"e_1_2_11_30_2","volume-title":"Summary of Product Characteristics: Tritace 10 mg Tablets (Ramipril)","author":"Aventis Pharma Ltd","year":"2007"},{"key":"e_1_2_11_31_2","volume-title":"Summary of Product Characteristics: Natrilix SR 1.5 mg Tablets","author":"Les Laboratoires Servier","year":"1996"},{"key":"e_1_2_11_32_2","volume-title":"Summary of Product Characteristics: Natrilix 2.5 mg Tablets","author":"Les Laboratoires Servier","year":"1977"},{"key":"e_1_2_11_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003823.pub2"},{"key":"e_1_2_11_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199816110-00015"},{"key":"e_1_2_11_35_2","first-page":"1083","article-title":"B\u00e9n\u00e9fice Th\u00e9rapeutique D\u2019une Faible Dose D\u2019indapamide: R\u00e9sultats D\u2019une \u00c9tude Europ\u00e9enne Contr\u00f4l\u00e9e en Double Aveugle Contre Placebo","volume":"88","author":"Asmar R.","year":"1995","journal-title":"Archives des Maladies du Coeur et des Vaisseaux"},{"key":"e_1_2_11_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199810000-00023"},{"key":"e_1_2_11_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002096"},{"key":"e_1_2_11_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-021-00385-w"},{"key":"e_1_2_11_39_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01290"},{"key":"e_1_2_11_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2006.04.006"},{"key":"e_1_2_11_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-022-03369-0"},{"key":"e_1_2_11_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-017-0665-4"},{"key":"e_1_2_11_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1555-z"},{"key":"e_1_2_11_44_2","first-page":"31","article-title":"Persistence With Treatment for Hypertension in Actual Practice","volume":"160","author":"Caro J. J.","year":"1999","journal-title":"Canadian Medical Association Journal"},{"key":"e_1_2_11_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab899"},{"key":"e_1_2_11_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13167-010-0050-1"},{"key":"e_1_2_11_47_2","volume-title":"The United Kingdom: Health System Summary","author":"Anderson M.","year":"2022"},{"key":"e_1_2_11_48_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2013-000373"},{"key":"e_1_2_11_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew293"},{"key":"e_1_2_11_50_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1836151"}],"container-title":["International Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/ijhy\/1999424","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/ijhy\/1999424","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/ijhy\/1999424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:32:17Z","timestamp":1784007137000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/ijhy\/1999424"}},"subtitle":[],"editor":[{"given":"Sreeja","family":"Dattachoudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1155\/ijhy\/1999424"],"URL":"https:\/\/doi.org\/10.1155\/ijhy\/1999424","archive":["Portico"],"relation":{},"ISSN":["2090-0384","2090-0392"],"issn-type":[{"value":"2090-0384","type":"print"},{"value":"2090-0392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-11-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1999424"}}